For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo | Placebo 200 mg BID for 5 days | None | None | 0 | 15 | 5 | 15 | View |
| Retapamulin 5 Days | Retapamulin ointment, 1% 200 mg BID 5 days | None | None | 1 | 19 | 10 | 19 | View |
| Retapamulin 3 Days | Retapamulin ointment, 1% 200 mg BID 3 days and 200 mg Placebo BID for 2 days | None | None | 0 | 23 | 6 | 23 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Abdominal Pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA 10.0 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Nasal Discomfort | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Rhinorrhoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Sneezing | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Epistaxis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Nasal Congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Pharyngolaryngeal Pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 10.0 | View |
| Burning Sensation | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 10.0 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 10.0 | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 10.0 | View |
| Paraesthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 10.0 | View |
| Paraesthesia | None | Nervous system disorders | None | View |
| Asthenia | None | General disorders | None | View |
| Ill-defined disorder | None | General disorders | None | View |
| Rhinitis | None | Infections and infestations | None | View |
| Viral infection | None | Infections and infestations | None | View |
| Contusion | None | Injury, poisoning and procedural complications | None | View |
| Post procedural complication | None | Injury, poisoning and procedural complications | None | View |
| Arthralgia | None | Musculoskeletal and connective tissue disorders | None | View |
| Back pain | None | Musculoskeletal and connective tissue disorders | None | View |
| Dermatitis allergic | None | Skin and subcutaneous tissue disorders | None | View |
| Pruritus allergic | None | Skin and subcutaneous tissue disorders | None | View |
| Urticaria | None | Skin and subcutaneous tissue disorders | None | View |
| Lymphadenopathy | None | Blood and lymphatic system disorders | None | View |
| Palpitations | None | Cardiac disorders | None | View |
| Blepharitis | None | Eye disorders | None | View |
| Gastrooesophageal reflux disease | None | Gastrointestinal disorders | None | View |